ClinicalTrials.gg
RecruitingNCT06329063Updated Apr 11, 2024

Oral Vasopressin Modulates Neural Responses to Looming Visual Stimuli: An Eye-tracking Study

An interventional study of Vasopressin and Placebo in Healthy, sponsored by University of Electronic Science and Technology of China. Recruiting at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by University of Electronic Science and Technology of China · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing Arginine Vasopressin in Diabetes Insipidus — 12 open to participants now, 12 under way, 2 of them phase 3. Arginine Vasopressin · Diabetes Insipidus.

Planned enrollment
25th of 43
80 · median 105
Started
2024
with 3 others
No phase
17 of 43
5 open now
Primary completion
2025-06
later than 2 of 11 live
Registered
38th of 43
by date
Lead sponsor
7 of 43
University of Electronic Science and Technology of China

Among the 43 studies testing Arginine Vasopressin in Diabetes Insipidus, this one is the 25th largest by planned enrollment, is one of 4 that started in 2024, is one of 17 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 38th registered.

Diabetes Insipidus

191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.

Browse Diabetes Insipidus studies →

Open to participants now

12 of the 43 studies testing Arginine Vasopressin in Diabetes Insipidus are open now, in 5 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Arginine Vasopressin

Arginine Vasopressin: first FDA approval 2020 (VASOPRESSIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Diabetes Insipidus studies recruiting now, 16 (53%) set no upper age limit and 11 (37%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing Arginine Vasopressin in Diabetes Insipidus, or all of them as a file.
02

Study summary

The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on the perception of time-to-collision of threatening and non-threatening stimuli by combining a validated looming fear eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.

Read the detailed description

Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. At the same time, the visual system's remarkable ability to perceive and interpret impending threats, notably through the "looming" phenomenon- a distinct pattern of optical expansion on the retina as objects approach, theoretically allows for precise estimation of the time-to-collision (TTC). It was recently demonstrated that the affective content of looming stimuli influences perceived TTC, with threatening objects judged as approaching sooner than non-threatening objects, hinting at a nuanced interaction between emotional valence and temporal perception. Within this context the present study aims to validate the effects of orally administered on the perception of time-to-collision of threatening and non-threatening stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a looming visual stimuli task 45 minutes after administration. The task paradigm will encompass threatening (butterfly, rabbit) and non-threatening (spider, snake) stimuli

03

Conditions studied

  • Healthy

Browse trials for

Keywords

  • Eye-tracking
  • vasopressin
  • looming fear
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written .
  • Normal or corrected-normal version

Exclusion criteria

Exclusion Criteria:

  • History of neuropsychiatric diseases.
  • History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
  • History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
  • History of renal diseases, including renal stones or renal failure.
  • History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
  • Known or allergic reaction to any medication or hormone; strong allergic reaction to food.
  • Infections such as COVID-19 or influenza, or unexplained fever.
  • Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
  • History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Vasopressin group

    Drug: Vasopressin (20IU)

    Drug: Vasopressin

  • Placebo comparator
    Placebo group

    Drug: Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio of judged-time-to-collision to actual-time-to-collision for threatening versus non-threatening stimuli after oral vasopressin administration

    Comparison of the ratio between the judged time to collision and the actual time to collision between the treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.

    Time frame: 75 minutes - 105 minutes after treatment

Secondary outcomes

  1. First saccade latency(ms) for threatening versus non-threatening stimuli after oral vasopressin administration

    Comparison of first saccade latencies between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.

    Time frame: 75 minutes - 105 minutes after treatment

  2. Fixation duration(ms) for threatening versus non-threatening stimuli after oral vasopressin administration

    Comparison of mean fixation durations between treatment groups for threatening (spider, snake) and non-threatening (rabbit, butterfly) stimuli.

    Time frame: 75 minutes - 105 minutes after treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jun 2025, 14 months after the start.

Of 37 non-industry interventional studies with no phase under Diabetes Insipidus, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 44. This study's planned 14 months is below that.

Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 8 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2024
First posted
Mar 25, 2024
StartActual
Mar 5, 2024
Primary completionEst.
Jun 1, 2025
CompletionEst.
Jul 30, 2025
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06329063
Responsible party
Benjamin Becker (Professor, University of Electronic Science and Technology of China) — Principal investigator
First posted
Mar 25, 2024
Start date
Mar 5, 2024
Primary completion
Jun 1, 2025 (estimated)
Completion
Jul 30, 2025 (estimated)
Last update
Apr 11, 2024

Study contacts

Weihua Zhao, Dr
Contact
zarazhao.uestc@outlook.com
86-28-61830811
Benjamin Becker, Dr
principal investigator · University of Electronic Science and Technology of China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine Vasopressin

Start the discussion